Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2000
11/15/2000EP1051405A2 Novel dihydroxyhexanoic acid derivatives
11/15/2000EP1051399A1 Phenylalanine derivatives useful as pharmaceutical agents
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051192A2 Methods for the prevention and treatment of fibrosis and sclerosis
11/15/2000EP1051191A2 Cd154 blockade therapy for pancreatic islet tissue transplantation
11/15/2000EP1051190A1 Vaccine compositions for mucosal administration comprising chitosan
11/15/2000EP1051189A2 Vaccine formulations
11/15/2000EP1051177A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051156A2 Pharmaceutical compositions
11/15/2000EP1051155A1 Nasal solutions
11/15/2000EP0650371B1 Covalent polar lipid-peptide conjugates for biological targeting
11/14/2000US6147255 Topical and systemic treatment of dermatological complaints associated with keratinization disorder which has effect on differentiation and on proliferation
11/14/2000US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
11/14/2000US6147223 Lactacystin analogs
11/14/2000US6147217 Synthesis of terfenadine and derivatives
11/14/2000US6147188 Irreversible cathepsin or calpain inhibitors
11/14/2000US6147187 Major histocompatibility complex proteins; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147096 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
11/14/2000US6147080 Inhibitors of p38
11/14/2000US6147073 Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/14/2000US6146845 Polynucleotides encoding a sialoadhesin family member-2 (SAF-2)
11/14/2000US6146837 Detecting fc gamma receptor (cd64) in a biological sample by conacting sample with cyanin compound, cy5; illuminating the sample with light of an appropriate excitation wavelength; and detecting fluorescence
11/14/2000US6146827 Detecting nucleic acid involved in g protein mediated signal transduction in a t helper cell sample
11/14/2000US6146658 Prodrugs, their preparation and use as pharmaceuticals
11/14/2000US6146633 Endogenous and exogenous proteins, and fragments are chemically modified outside the body of an animal so that when injected into the animal, they produce more antibodies against the unmodified protein unmodified protein alone
11/14/2000US6146632 Vaccines
11/14/2000US6146631 Administering a fusion protein comprising a gelonin prefered amino acid sequeance, a targeting sequence that allows internalization of fusion protein in the cell, internizing the fusion protein in the cell, eliminating the cell
11/14/2000US6146630 Inhibitors for the adhesion of lymphocytes to glandular cells
11/14/2000US6146622 Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
11/09/2000WO2000066754A1 Protein c derivatives
11/09/2000WO2000066737A1 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY
11/09/2000WO2000066715A1 Method for diminishing specific immune reactions
11/09/2000WO2000066708A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066559A1 Piperidine derivatives useful as ccr5 antagonists
11/09/2000WO2000066558A1 Piperazine derivatives useful as ccr5 antagonists
11/09/2000WO2000066522A1 Glucocorticoid receptor modulators
11/09/2000WO2000066179A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof
11/09/2000WO2000066162A1 Mutant human cd80 and compositions for and methods of making and using the same
11/09/2000WO2000066159A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/09/2000WO2000066158A2 Use of cytokines and mitogens to inhibit pathological immune responses
11/09/2000WO2000066156A1 Death domain containing receptor 5
11/09/2000WO2000066155A1 Methods for preventing reactivation of latent virus and controlling virus replication
11/09/2000WO2000066154A2 Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components
11/09/2000WO2000066151A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000WO2000066148A1 Novel proteins
11/09/2000WO2000066135A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000WO2000066134A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000WO2000066131A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide
11/09/2000WO2000066112A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics
11/09/2000WO2000066111A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
11/09/2000WO2000066107A2 Antimalarian agents for the treatment of asthma
11/09/2000WO2000066106A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
11/09/2000WO2000066104A2 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000WO2000066098A2 Vitamin d derivatives for the treatment of systemic lupus erythematosus
11/09/2000WO2000066094A2 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000WO2000066086A1 Anti-inflammatory bioactive glass particulates
11/09/2000WO2000066082A1 Anti-nausea compositions and methods
11/09/2000WO2000041720A8 Improved saponin adjuvant compositions and methods relating thereto
11/09/2000WO2000037094A3 Therapeutic applications of flint polypeptides
11/09/2000WO2000035472A3 Cytokine combination therapy
11/09/2000WO2000034477A3 Neuron-associated proteins
11/09/2000WO2000034447A3 Human ubiquitin ligase e3 for the modulation of nf-kappa b
11/09/2000WO2000032584A3 Nonsteroidal antiinflammatories
11/09/2000WO2000030671A3 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
11/09/2000WO2000027999A9 Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
11/09/2000WO2000021996A3 Methods and compositions for inhibiting neoplastic cell growth
11/09/2000WO2000015785A3 GENE MODIFICATION IN THE GENE FOR THE DIE Gβ3-SUB-UNIT OF HUMAN G-PROTEIN
11/09/2000WO2000010968A3 Novel aryl sulphonamide amino acid esters and analogues
11/09/2000WO2000001349A3 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
11/09/2000DE19922444A1 Verfahren zur Behandlung von TNF-Rezeptor vermittelten Krankheiten A method for the treatment of TNF-receptor-mediated diseases
11/09/2000CA2377131A1 Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components
11/09/2000CA2372956A1 Use of cytokines and mitogens to inhibit pathological immune responses
11/09/2000CA2372923A1 Dna encoding snorf36a and snorf36b receptors
11/09/2000CA2372803A1 Variants of traf2 which act as an inhibitor of tnf-alpha (tnf .alpha.) signaling pathway
11/09/2000CA2372772A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
11/09/2000CA2372387A1 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000CA2372225A1 Anti-nausea compositions and methods
11/09/2000CA2372223A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000CA2372220A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000CA2372173A1 Glucocorticoid receptor modulators
11/09/2000CA2371766A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof
11/09/2000CA2371421A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/09/2000CA2370821A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000CA2370587A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000CA2370304A1 Specific antibodies and antibody fragments for tgf.beta.1
11/09/2000CA2369747A1 Mutant human cd80 and compositions for and methods of making and using the same
11/09/2000CA2369526A1 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000CA2369371A1 Death domain containing receptor 5
11/09/2000CA2338799A1 Protein c derivatives
11/09/2000CA2336362A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide
11/08/2000EP1050540A2 Inhibitors of dipeptidyl-aminopeptidase type IV
11/08/2000EP1050307A1 CCR4 antagonists in sepsis
11/08/2000EP1050306A1 CYTOKINE INDUCERS COMPRISING M161Ag
11/08/2000EP1050301A1 Medicinal compositions
11/08/2000EP1049782A1 Mutants of il-16, processes for their production, and their use
11/08/2000EP1049776A1 Phagocytosis genes and uses thereof
11/08/2000EP1049770A1 Secreted proteins and polynucleotides encoding them
1 ... 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 ... 1172